Target intelligence / Profile preview

T-type calcium channel subunit alpha-1H (commonly referred to as CaV3.2) (CaV3.2)

Target
CaV3.2
Molecular classification
Ion channel, Voltage-gated calcium channel, T-type calcium channel, Low-voltage activated (LVA) calcium channel
01

Overview

The T-type calcium channel Cav3.2 subunit is a low-voltage activated, voltage-dependent calcium channel encoded by the CACNA1H gene. It comprises a pore-forming α1H subunit and serves as the principal molecular entity responsible for transient, low-threshold calcium currents in excitable cells, including neurons and cardiac pacemaker cells. Cav3.2 regulates the initiation and propagation of electrical signals, contributing to neuronal firing, neurotransmitter release, pacemaker activity, and sleep-wake oscillations. Cav3.2 is considered a promising therapeutic target for epilepsy and pain by virtue of its pivotal role in cellular excitability, with structure-based drug discovery ongoing for selective modulators. Dysfunction of Cav3.2 is implicated in neurological, cardiac, and sensory disorders, although current pharmacological agents have significant limitations, including selectivity and safety concerns.

Other names
T-type calcium channel α1H subunitCalcium channel, voltage-dependent, T type, alpha 1H subunitCACNA1H (gene symbol for human CaV3.2)
02

Mechanism of action

Inhibition/blockade of the channel pore, preventing Ca²⁺ influx; State-dependent modulation (some ligands preferentially bind when the channel is open/inactive); Modulation of channel gating via phosphorylation or protein-protein interactions; Potential indirect modulation by G protein-coupled receptor signaling

03

Biological functions

Regulation of neuronal excitabilityControl of pacemaking activity in cardiac and neuronal tissueModulation of neurotransmitter releaseMediation of low-threshold Ca²⁺ currentsParticipation in sleep-wake cycle regulationSignal transductionFacilitating cellular oscillatory behavior
04

Disease associations

Epilepsy (especially absence seizures)Neuropathic painOther pain conditionsNeurodevelopmental and neuropsychiatric disorders (emerging evidence)Cardiovascular disease (rhythm disturbances, especially pacemaking)
05

Safety considerations

Off-target effects: T-type antagonists, including non-selective agents, may affect other calcium channels, leading to cardiac rhythm disturbancesCNS side effects: Sedation, cognitive impairment, or motor disturbance possible with systemic Cav3.2 blockadeCardiovascular concerns: Potential for bradycardia or arrhythmia due to pacemaking roleLack of highly selective agents limits therapeutic index
06

Interacting drugs

ACT-709478 (T-type calcium channel antagonist)

4 more in the full profile.

07

Biomarkers

CACNA1H gene expression/mutation analysis for epilepsy/neuropathic pain susceptibilityChannel phosphorylation state in pathophysiology (e.g., neuroexcitability disorders)No widely validated clinical biomarkers for patient selection available at present

Beyond the preview

Go deeper on T-type calcium channel subunit alpha-1H (commonly referred to as CaV3.2) (CaV3.2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on T-type calcium channel subunit alpha-1H (commonly referred to as CaV3.2) (CaV3.2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call